

D E P O S I T A R Y R E C E I P T S

ATTENTION: **EUROPEAN** RESEARCH, SALES, TRADING
AND OPERATIONS STAFF

MERGER**GLAXO WELLCOME PLC**

Please be advised of the following terms of the Glaxo Wellcome plc and SmithKline Beecham plc merger into a newly formed holding company, **GlaxoSmithKline plc**

Effective December 27, 2000, each American Depositary Share (ADS) of Glaxo Wellcome plc will be converted into 1 ADS of GlaxoSmithKline plc. There will not be an exchange of certificates. New certificates have been ordered.

The Cusip for Glaxo Wellcome plc will remain the same for GlaxoSmithKline: **37733W 10 5**. The New Symbol for GlaxoSmithKline will be **GSK**.

Each American Depositary Share (ADS) of SmithKline Beecham plc will be converted into 1.138 ADS of GlaxoSmithKline plc. No fractional ADSs will be issued. Instead cash payment in lieu of any fractional ADSs will be paid. SmithKline Beecham ADSs will need to be exchanged for GlaxoSmithKline ADSs. The Tender & Exchange Department is acting as the exchange agent.

If you require any additional information please visit our website at **www.adrbny.com** or feel free to contact:

New York

Steven Farber
Assistant Vice President
Sfarber@bankofny.com
Tel: (212) 815-3874

Daniel Torrey
Assistant Vice President
Dtorrey@bankofny.com
Tel. (212) 815-4330

London

Michael McAuliffe
Vice President
Mmcauliffe@bankofny.com
Tel: 442 07 964 6336

James T. Green
Vice President
Jgreen@bankofny.com
Tel: 442 07 964 6080

www.adrbny.com

**THE
BANK OF
NEW
YORK**